WASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in other folks with moderate to excessive Crohn's Read More
Tags :Mirikizumab
WASHINGTON, DC — The selective interleukin (IL)–23p29 monoclonal antibody mirikizumab demonstrated safety and efficacy in other folks with moderate to excessive Crohn's Read More
